Cost-utilityGenotypingOvarian-cancer, diagnosisThe article reports on the findings by researchers from the University of Rochester School of Medicine that BRCA 1/2 genetic testing of women at high risk of carrying the BRCS 1 or 2 gene mutations, and treatment of those who test positive, seems ...
Objectives: Genetic mutations in breast cancer susceptibility genes BRCA1/2 are associated with an increased risk of breast/ovarian cancers. Cost-effectiv... ML Holland,A Huston,K Noyes - 《Value in Health》 被引量: 52发表: 2009年 Mutations of the BRCA1 and BRCA2 genes and the possibilitie...
Cost-Effectiveness Analysis of Testing for Brca1 and Brca2 Mutations In Women Diagnosed With Ovarian Cancer and Their Female First- And Second Degree Relat... Cost- Effectiveness Analysis of Testing for Brca1 and Brca2 Mutations In Women Diagnosed With Ovarian Cancer and Their Female First- And...
The test cost was calculated using the charge for full BRCA1/2 gene sequencing (Myriad Genetics, Inc.) multiplied by a Medicare-based cost-to-charge ratio. Counselors spent an average of 4.2 h providing genetic counseling for women at risk of having a susceptibility mutation. Genetic counseling...
DISCUSSION The results of this analysis indicate that if a population-wide screening program were implemented at a cost of $460 per gene test in the current cohort of American Ashkenazi Jewish fe- males aged 35–55 years, which numbers about 0.96 million women, then 2,811 ovarian cancers ...
To evaluate the long-term cost-effectiveness of germlineBRCA1andBRCA2(collectively termed "BRCA") testing in women with epithelial ovarian cancer, and test... A Eccleston,A Bentley,M Dyer,... - 《Value in Health》 被引量: 7发表: 2017年 A Cost-Effectiveness Evaluation of Germline BRCA1 an...
Testing for germline BRCA1/2 mutations has an established predictive role in breast cancer risk assessment. More recently, studies have also identified BRCA1/2 status as clinically relevant in the selection of therapy for patients already diagnosed with
Testing for germline BRCA1/2 mutations has an established predictive role in breast cancer risk assessment. More recently, studies have also identified BRCA1/2 status as clinically relevant in the selection of therapy for patients already diagnosed with
BRCA genetic test, breast cancer, cost-effectiveness, ovarian cancer, preventive strategies.基因检测临床研究与应用结果介绍:尽管发达国家的 BRCA1/2 基因检测是遗传性乳腺癌和卵巢癌 (HBOC) 高危患者现实的一部分,但对于中高收入国家而言,情况并非如此。出于这个原因,本研究旨在评估 BRCA1/2 基因检测和针对 ...
JAMA Network Open Research December 30, 2024 Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer JAMA Network Open Research September 3, 2024 Cost-Effectiveness of Gene-Specific Prevention for Ovarian and Breast Cancer JAMA Network Open Research February 9, 2024JAMA...